# The Food and Drug Administration approved a label expansion for Vyvgart.

*biotech · news · 2026-05-08 · MarketScreener*

## Key points

- The FDA approved a label expansion for Argenx's Vyvgart and Vyvgart Hytrulo treatments.
- Vyvgart is now indicated for all serotypes of adult generalized myasthenia gravis patients.
- The expanded approval is based on data from Argenx's Phase 3 clinical study.
- Patients treated with Vyvgart in the study showed rapid and sustained symptom improvement.

By Christopher Kuo Argenx SE said the Food and Drug Administration approved a label expansion for Vyvgart and Vyvgart Hytrulo, the company's treatments for a rare, chronic autoimmune disorder known as generalized myasthenia gravis. The approved supplemental Biologics License Application expands Vyvgart's indication to include all serotypes of adult patients living with generalized myasthenia gravis, a disease that can result in debilitating and life-threatening muscle weakness, the company said Friday. The approval is based on data from the company's Phase 3 study, in which patients treated with Vyvgart showed rapid and sustained improvements in their disease symptoms, the company said. Write to Christopher Kuo at chris.kuo@wsj.com (END) Dow Jones Newswires 05-08-26 1755ET

**Companies:** Argenx SE

[Read the full story on MarketScreener](https://www.marketscreener.com/news/fda-approves-label-expansion-for-argenx-treatment-of-autoimmune-disease-ce7f5bdbd18cf225)

---

Canonical: https://newsio.io/n/a9787570-0877-4502-a3fa-f505a1b4ed8b/the-food-and-drug-administration-approved-a-label-expansion-for-vyvgart-the-comp
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works